RxDoctor Payments DataLook up a doctor →

Rosa Vizcarra, MD

Geriatric Medicine · San Antonio, TXNPI 1649206087

Payments from drug & device makers

$9,303in general payments, 2019–2025

Across 408 payments — averaging $22.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Amgen$1K
  • Lilly USA, LLC$697
  • GSK$467
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$9,303100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,303 in reported general payments places this provider in the 95th percentile of 275 geriatric medicine providers in Texas.

See all geriatric medicine providers in Texas

Medicare billing

Part B allowed, 2024
$190,061
Medicare patients
306
Services billed
2,839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide125$161,309
JardianceEmpagliflozin91$117,684
FarxigaDapagliflozin Propanediol102$100,580
RybelsusSemaglutide40$55,414
MounjaroTirzepatide48$53,409
AbrysvoRsv Vacc, Pref A And Pref B/Pf147$46,929
ProliaDenosumab20$34,753
JanuviaSitagliptin Phosphate24$28,278
TrulicityDulaglutide13$27,110
EliquisApixaban36$21,624
Breo ElliptaFluticasone/Vilanterol35$19,408
Repatha SyringeEvolocumab15$15,989
ShingrixVaricella-Zoster Ge/As01b/Pf56$12,487
Xigduo XrDapaglifloz Propaned/Metformin21$12,322
SynjardyEmpagliflozin/Metformin Hcl17$12,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,726$216,723165 claims
Boehringer IngelheimJardiance, Synjardy$261$129,945108 claims
AstraZenecaFarxiga, Nexium$1,248$103,725114 claims
Lilly USA, LLCMounjaro, Trulicity$697$80,51961 claims
PfizerAbrysvo, Eliquis$233$68,553183 claims
GSKBreo Ellipta, Shingrix, Trelegy Ellipta$467$42,313107 claims
AmgenProlia$1,145$34,75320 claims
MerckJanuvia$28$28,27824 claims
Astellas Pharma US IncMyrbetriq, Veozah$84$16,27625 claims
AbbVieSynthroid$1,353$3,25750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 275 geriatric medicine providers in Texas.

Other geriatric medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →